Prior sleep-wake behavior predicts mental health resilience among adults in the United States during the COVID-19 pandemic

Introduction

Absent widespread testing or safe and effective coronavirus disease 2019 (COVID-19) vaccines in early 2020, stringent mitigation policies were implemented in the United States and around the world to contain transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19. Among the many consequences of these measures was an enhanced opportunity for self-selection of sleep-wake timing, resulting from work-at-home directives, reduced travel and commutes, school closures, and stay-at-home orders. Survey data (1-7) and longitudinal wearable or mobile application data (8-12) have been used to report increased sleep duration and delayed sleep timing during this interval, in the U.S. and other countries. Simultaneously, population-level surveillance studies revealed considerably elevated levels of adverse mental health symptoms and substance use among U.S. adults, including three-to four-fold times the prevalence of anxiety and depression symptoms and two times the prevalence of suicidal ideation in the second quarter of 2020 compared to that of 2019 (13-15).

Prior to the pandemic, associations between impaired sleep (e.g., sleep disturbance and insufficient sleep) and adverse mental and behavioral health symptoms (e.g., anxiety symptoms, depression symptoms, substance use, and suicidal ideation) were well established (16). In anticipation of mental health challenges in the wake of the onset of the COVID-19 pandemic and stringent mitigation measures, characterizing optimal sleep-wake structures for a mentally healthy life was among multidisciplinary research priorities posed to minimize adverse mental health effects of the pandemic (17). Indeed, during the initial phase of the COVID-19 pandemic, links between poor-quality and insufficient sleep and adverse mental and behavioral health symptoms were reported based on survey data (5, 18-20). However, self-reported sleep-wake data may be subject to various biases (21-24). Moreover, these studies did not include measures of variability in sleep timing, for which emerging evidence has identified associations with depressed mood (25-28) and other adverse health outcomes (29-31).

In the present study, we examined objective sleep and mental health among U.S. users of a validated sleep wearable (WHOOP, Boston, Massachusetts) (32, 33) before and during the COVID-19 pandemic using a comprehensive set of sleep variables (duration, sleep onset, sleep offset, consistency of sleep timing, and wake after sleep onset). Our findings align with data from other sources (1-12) demonstrating on average increased sleep duration and delayed sleep timing during the pandemic, and extend the existing literature by revealing increased consistency of sleep timing. Moreover, we found that participants with persistent sleep deficiency and low sleep consistency had higher odds of adverse mental health symptoms, and that anxiety or depression symptoms were associated with decreased sleep duration from moderate (6-7h) to short (<6h) and decreased consistency of sleep timing from moderate (70-80 out of 100) to low (<70). These findings support further investigations of sleep as a modifiable risk factor that could be targeted by behavioral interventions designed to enhance mental health resilience.

Results

During June 24-30, 2020, 20,717 of 139,237 eligible invited active U.S. WHOOP users aged ≥18 years completed Internet-based surveys (response rate = 14.9%, Fig. S1). Overall, 4,912 (23.7%) participants had nocturnal sleep episodes recorded for ≥70% of nights throughout each of three intervals (pre-pandemic [January 1 to March 12, 2020]; acute pandemic onset [March 13 to April 12, 2020]; early chronic pandemic [April 13 to June 30, 2020]). Of these, 3,845 (78.3%) also completed the 4-item Patient Health Questionnaire to screen for symptoms of anxiety and depression (34). The sample comprised 3,471 (70.7%) male and 3,802 (77.2%) non-Hispanic White (White) adults. Most participants were highly educated (n = 4,105 [83.6%] college-educated), employed (n = 4,417 [89.9%]), and reported high household income (e.g., ≥USD$100,000, n = 3,126 [65.5%]). Mean age was 39.7 ± 11.24 years (Table S1). See Fig. S1 for the survey flow and Table S1 for detailed participant characteristics.

Overall, compared to the 6.95 ± 0.687 h mean sleep duration in the pre-pandemic interval, mean sleep duration was 0.25 h (95% CI = 0.237 to 0.270, p < 0.0001) longer in the acute pandemic interval, and 0.09 h (95% CI = 0.076 to 0.107, p < 0.0001) longer in the early chronic pandemic interval (Fig. 1A, Table S2). In the overall sample, mean sleep duration remained significantly longer on weekend nights compared with weeknights (except for holidays), though the magnitude of difference dampened with time (Fig. 1A). Sleep consistency (scored on a 0 to 100 scale), which was generally lower on weekend nights compared to weeknights, increased during both COVID intervals compared to the pre-pandemic interval, increased by 3.51 points (95% CI = 3.295 to 3.728 p < 0.0001) in the acute pandemic interval, and 4.06 points (95% CI = 3.856 to 4.267, p < 0.0001) in the early chronic pandemic interval (Fig. 1B, Table S2). Wake after sleep onset (WASO) decreased by 0.05 h (95% CI = 0.031 to 0.074, p < 0.0001) in the acute pandemic interval compared to the pre-pandemic interval but did not between the early chronic pandemic and pre-pandemic intervals (difference = 0.01 h, 95% CI = -0.022 to -0.045, p > 0.99) (Fig. 1C, Table S2). Finally, sleep timing abruptly shifted to a later time (i.e., delayed) immediately following the declaration of the pandemic by the World Health Organization (WHO) on March 12, 2020, and over the course of the month, mean sleep onset was 18 m later (95% CI = 17.384 to 20.045, p < 0.0001) and sleep offset was 36 m later (95% CI = 35.111 to 38.106, p < 0.0001) compared to the pre-pandemic interval (Fig. 1D, Table S2). The delay in sleep onset was sustained throughout the early chronic pandemic interval (17 m [95% CI = 16.470 to 19.289, p < 0.0001]), while the delay in sleep offset attenuated to 25 m during that time (95% CI = 23.629 to 26.714, p < 0.0001).

• Download figure
• Open in new tab

Fig. 1. Sleep duration, consistency, wake after sleep onset, and timing, January 1, 2020—June 30, 2020.

While in the overall sample we observed longer sleep duration, increased consistency of sleep timing, relatively unchanged WASO, and delayed timing during the COVID-19 pandemic intervals, a subset of participants experienced marked changes in the opposite directions (Fig. 2). We therefore examined deciles of participants (n = 491) with the highest-magnitude changes in sleep duration, consistency, and WASO. The deciles with the highest-magnitude changes in sleep duration were lengthened or shortened by 0.77 h (95% CI = 0.742 to 0.794, p < 0.0001) and 0.50 h (95% CI = 0.522 to 0.470, p < 0.0001), respectively, while the deciles with the highest-magnitude changes in sleep consistency were increased and decreased by 12.85 points (95% CI = 12.480 to 13.214, p < 0.0001) and 4.41 points (95% CI = 4.720 to 4.099, p < 0.0001), respectively (Table S3). Regarding sleep timing, the deciles with the largest delays in sleep onset and offset shifted by 1 h 21 m (22:57 to 00:18, 95% CI = 77.284 to 84.861 m, p < 0.0001) and 1 h 39 m, (06:40 to 08:19, 95% CI = 95.456 to 102.811 m, p < 0.0001) respectively. The deciles with the largest advances in sleep onset and offset shifted by 33 m (23:29 to 22:55, 95% CI = 30.942 to 36.385 m, p < 0.0001) and 28 m (07:12 to 06:43, 95% CI = 26.036 to 31.358 m, p < 0.0001), respectively.

• Download figure
• Open in new tab

Fig. 2. Heterogeneity in changes to sleep duration, consistency, and timing.

Of the 3,845 participants who completed the PHQ-4, 755 (19.6%) screened positive for anxiety or depression symptoms, 1,299 (33.8%) screened positive for COVID-19 trauma- and stressor-related disorder (TSRD) symptoms, 1,208 (32.4%) screened positive for burnout symptoms, and 856 (22.4%) reported that they had started or increased substance use to cope with stress or emotions related to the pandemic (Table S2).

Multivariable analysis including demographic variables and sleep (during both the pre-pandemic, and acute pandemic onset, and early chromic pandemic intervals) or lifestyle variables (i.e., physical activity, alcohol intake) revealed that sleep duration and consistency, along with physical activity, were associated with differences in odds of anxiety or depression symptoms, onset or increased substance use, and burnout symptoms (Table). Regarding sleep duration, compared with participants who slept >7 h in both intervals, individuals who slept <6 h in both intervals had higher odds of anxiety or depression symptoms (aOR = 1.75, 95% CI = 1.14 to 2.69, p = 0.007) and burnout symptoms (aOR = 1.57, 95% CI = 1.07 to 2.29, p = 0.016), as did those who slept 6 to 7 h and those who experienced a decrease in peri-pandemic sleep duration to <6 h from 6-7 h (e.g., burnout symptoms, aOR = 2.22, 95% CI = 1.32 to 3.71, p = 0.001).

Regarding consistency of sleep timing, compared with participants with sleep consistency >80 in both intervals, individuals with sleep consistency <70 in both intervals had higher odds of all three assessed adverse mental and behavioral health symptoms (e.g., onset or increased substance use, aOR = 2.17, 95% CI = 1.48 to 3.19, p < 0.0001). Odds of new or increased substance use were also higher among individuals with sleep consistency of 70-80 during both intervals (aOR = 1.46, 95% CI = 1.06 to 2.01, p = 0.016), and odds of anxiety or depression symptoms were higher among individuals whose sleep consistency decreased from 70-80 in the pre-pandemic interval to <70 in the early chronic pandemic interval (aOR = 2.07, 95% CI = 1.17 to 3.67, p = 0.0009). Odds of adverse mental or behavioral health symptoms were not higher for individuals with decreases in sleep duration or sleep consistency who had optimal duration (>7 h) or consistency (>80) in the pre-pandemic interval, regardless of the magnitude of peri-pandemic decrease.

Discussion

Among nearly 5,000 active users of a validated sleep wearable with data preceding the onset of the COVID-19 pandemic, we found an acute increase in mean sleep duration and delay in sleep timing in the month when stringent mitigation policies were initially implemented widely across the United States, consistent with literature from the U.S. and around the globe (1-12). Using a novel metric to quantify the consistency of sleep timing modified from the Sleep Regularity Index (30) to account for recency in the weights of comparator sleep episodes, we also found an abrupt and sustained increase in sleep consistency during the pandemic. Across the sample, the magnitude of the increase in mean sleep duration decreased gradually in the subsequent two months, as the mean sleep offset returned to near pre-pandemic times, while the delay in sleep onset persisted. Adverse mental and behavioral health symptoms, including anxiety and depression symptoms; onset, or increased substance use to cope with stress or emotions; and burnout symptoms were associated with pre-pandemic sleep deficiency and inconsistent sleep, but not acute decreases in sleep duration or sleep consistency experienced during the pandemic. These findings indicate that recent past sleep-wake behavior was associated with mental health resilience in response to profound lifestyle changes, such as the stringent social and behavioral interventions (e.g., stay-at-home orders, work-from-home directives) implemented to reduce SARS-CoV-2 transmission during the COVID-19 pandemic.

Analysis of participants with high-magnitude changes to sleep measures revealed disparate changes to sleep during the pandemic, with some participants decreasing in sleep duration and consistency at the onset of the pandemic when there were increases in these measures, on average. Interestingly, whereas participants with substantial increases in these sleep measures exhibited sudden changes immediately following the global pandemic declaration, individuals with substantial decreases exhibited more gradual and persistent decreases. The more consistent trajectory and lack of response to the pandemic declaration suggest that these changes may have contributing factors independent of the pandemic and its mitigation. Given the association between chronic insufficient (25, 35) or inconsistent sleep (25-28) and adverse mental and behavioral health symptoms, differences in changes to sleep during the pandemic may have implications for mental health and are particularly relevant for identifying potential targets for modifiable risk factors. Adjusting for demographic and other lifestyle variables, participants with shorter pre-pandemic sleep duration or lower pre-pandemic consistency of sleep timing had higher odds of adverse mental health symptoms during the early chronic phase of the COVID-19 pandemic compared to participants who attained the recommended sleep duration (>7 h (36)) or high sleep consistency during both intervals. In contrast, participants who had obtained the recommended sleep duration pre-pandemic and participants who had recorded >80 sleep consistency pre-pandemic did not have higher odds of adverse mental health symptoms compared if these sleep measures declined during the pandemic. Together, these results suggest that pre-pandemic sleep duration and consistency may have provided participants with mental health resilience during the initial phase of the pandemic, even among those who experienced worsened sleep during this time.

These findings suggest that sleep could be a modifiable risk factor (1) to be targeted by behavioral interventions designed to enhance mental health resilience (37). At a time when the prevalence of adverse mental and behavioral health symptoms among U.S. adults has increased several-fold (13-15, 19, 38, 39), and non-modifiable risk factors with potential long-term impacts have been introduced (40), the value of modifiable mental health risk factors is of critical importance. Insufficient sleep duration and inconsistent sleep timing are highly prevalent in modern society (41). Alongside many undesirable changes during the COVID-19 pandemic has been a unique opportunity for some to improve sleep behaviors, as demonstrated in our and other studies (1-6, 8-12). Our unique dataset linking mental health and objective high-resolution pre-pandemic sleep-wake data enhances our understanding of the relationships between sleep behaviors and mental health (42), including before, during and after the onset of the COVID-19 pandemic (18). Importantly, there is evidence supporting the efficacy of cognitive and behavioral interventions to improve sleep in adults without sleep disorders (43), providing a precedent for effective measures, including for improvement of sleep to enhance mental health (44). Furthermore, improving sleep may have additional benefits for other major aspects of health, including immune function, cardiovascular health, and diabetes (42), as well as cognitive function (45).

Strengths of this study include the use of objective sleep measures, inclusion of pre-pandemic comparator sleep data, large sample size, psychometrically validated mental health screening instruments, and inclusion of demographic and lifestyle-related variables (i.e., physical activity, alcohol consumption) in multivariable models assessing associations with a comprehensive set of sleep variables (i.e., duration, timing, consistency) (46, 47). Limitations of this study include a lack of pre-pandemic comparator mental health data, non-random recruitment methods and potential seasonal influences on sleep and mood. Regarding the first, the cross-sectional mental health measures preclude a causal interpretation of findings related to mental health. Regarding the second, most sample participants were male, highly educated, employed, and reported higher than the national average household income. Given that income was highly predictive of changes in mobility during the pandemic, with wealthy areas exhibiting larger mobility reductions (48), effects on sleep of stay-at-home orders may be overrepresented in this sample. Moreover, given that WHOOP is a subscription tracker of sleep and fitness, participants may have been more knowledgeable about and motivated to pursue optimal sleep health and fitness than the general United States adult population, which could limit the generalizability of these findings. However, most of the demographic differences in adverse mental health symptom prevalence (e.g., by gender, age, and diurnal preference) were consistent with evidence from the general population (13-15, 19). Finally, it is possible that sleep and mental health responses to the onset of a pandemic may vary with season and be influenced by daylight savings time changes; however, 2019 and 2020 data on time in bed and sleep timing from Capodilupo and Miller (2021) indicate that the magnitude of changes to sleep-wake behavior observed in the months after the COVID-19 pandemic were not observed the year before (12). For example, in 2019, time in bed was slightly shorter during March 10 through May 15 compared to January 1 through March 9, 2019 (by 0.05 ± 0.003 h), and sleep offset time did not differ significantly between the intervals. Comparing the same intervals in 2020, time in bed was considerably longer during March 10 through May 15 (by 0.24 ± 0.003 h), and sleep offset was significantly later (by 29 ± 1 m) (12).

As policymakers grapple with decisions about balancing stringent mitigation measures during future waves of SARS-CoV-2 or other pathogens and mental health, communities, healthcare providers, and public health officials should consider the potential roles of sleep and circadian rhythms in mitigating potential mental health consequences. Future research should evaluate public health programs that include sleep and circadian health as a primary prevention strategy for adverse mental health outcomes and to improve resilience to acute stressors. Sleep duration, timing, and consistency may be modifiable risk factors for adverse mental health in response to stressful life events.

Materials and Methods

Author Contributions

Mark É. Czeisler: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Methodology, Visualization, Writing – original draft, Writing – review & editing: Emily R. Capodilupo: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Methodology, Visualization, Writing – review & editing: Matthew D. Weaver: Conceptualization, Formal Analysis, Visualization, Writing – review & editing: Charles A. Czeisler: Conceptualization, Funding acquisition, Methodology, Writing – review & editing: Mark E. Howard: Conceptualization, Funding acquisition, Methodology, Supervision, Writing – review & editing: Shantha M.W. Rajaratnam: Conceptualization, Formal Analysis, Funding acquisition, Methodology, Supervision, Visualization, Writing – review & editing

Competing Interest Statement

M.É.C., M.D.W., C.A.C., M.E.H., and S.M.W.R. reported receiving a grant from the CDC Foundation with funding from BNY Mellon and a gift from Hopelab, Inc. M.É.C. reported having received a grant from the Australian-American Fulbright Commission administered through a 2020 to 2021 Fulbright Scholarship funded by The Kinghorn Foundation and having received personal fees from Vanda Pharmaceuticals. E.R.C. is a paid employee of and has equity interest in WHOOP, Inc., and has equity interest in ARCHANGELS. M.D.W. reported consulting fees from National Sleep Foundation and the University of Pittsburgh. C.A.C. reported receiving grants to support The COVID-19 Outbreak Public Evaluation (COPE) Initiative and grants from Brigham and Women’s Physician’s Organization during the conduct of the study; being a paid consultant to or speaker for Ganésco, Institute of Digital Media and Child Development, Klarman Family Foundation, M. Davis and Co, Physician’s Seal, Samsung Group, State of Washington Board of Pilotage Commissioners, Tencent Holdings, Teva Pharma Australia, and Vanda Pharmaceuticals, in which C.A.C. holds an equity interest; receiving travel support from Aspen Brain Institute, Bloomage International Investment Group, UK Biotechnology and Biological Sciences Research Council, Bouley Botanical, Dr Stanley Ho Medical Development Foundation, Illuminating Engineering Society, National Safety Council, Tencent Holdings, and The Wonderful Co; receiving institutional research and/or education support from Cephalon, Mary Ann and Stanley Snider via Combined Jewish Philanthropies, Harmony Biosciences, Jazz Pharmaceuticals PLC, Johnson and Johnson, Neurocare, Peter Brown and Margaret Hamburg, Philips Respironics, Regeneron Pharmaceuticals, Regional Home Care, Teva Pharmaceuticals Industries, Sanofi S.A., Optum, ResMed, San Francisco Bar Pilots, Schneider National, Serta, Simmons Betting, Sysco, Vanda Pharmaceuticals; being or having been an expert witness in legal cases, including those involving Advanced Power Technologies; Aegis Chemical Solutions; Amtrak; Casper Sleep; C and J Energy Services; Complete General Construction; Dallas Police Association; Enterprise Rent-A-Car; Steel Warehouse Co; FedEx; Greyhound Lines; Palomar Health District; PAR Electrical, Product, and Logistics Services; Puckett Emergency Medical Services; South Carolina Central Railroad Co; Union Pacific Railroad; UPS; and Vanda Pharmaceuticals; serving as the incumbent of an endowed professorship provided to Harvard University by Cephalon; and receiving royalties from McGraw Hill and Philips Respironics for the Actiwatch-2 and Actiwatch Spectrum devices. C.A.C.’s interests were reviewed and are managed by the Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. S.M.W.R. reported receiving institutional consulting fees from CRC for Alertness, Safety, and Productivity; Teva Pharmaceuticals; Vanda Pharmaceuticals; Circadian Therapeutics; BHP Billiton; and Herbert Smith Freehills; receiving grants from Teva Pharmaceuticals and Vanda Pharmaceuticals; and serving as chair for the Sleep Health Foundation outside the submitted work. M.E.H. reports receiving: institutional consulting fees from Teva Pharmaceuticals, Biogen and Sanofi; and equipment to support research from Optalert and Philips Respironics outside the submitted work. No other potential conflicts of interest were reported.

Supplementary Information for

• Download figure
• Open in new tab

Fig. S1. Flow of the survey respondents